Biocon Biologics to raise $150 million from Goldman Sachs at $3.94 billion valuation
As per the terms of the proposed agreement, Goldman Sachs will be issued optionally convertible debentures at a post money equity valuation of $ 3.94 billion BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs, Transaction Values Biocon Biologics at USD 3.94 Billion. Biocon plans 2,000-crore capex for generics biz
Biocon has planned a cumulative capex of 2,000 crore for the generics business over the next three years.The company's overall capex in generics is s BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting Biocon ranked among top 5 global biotech employers for 2020
Biocon Ltd, a global biopharmaceuticals company, has been ranked among the Top 5 Global Biotech Employers for 2020 on the US-based Science magazine's
Biocon's partner Equillium gets USFDA nod to begin phase-3 trial of itolizumab on COVID-19 patients
The Phase 3 trial called as EQUINOX will enroll a total of 800 patients at sites in the United States and abroad and include interim assessments at 20 percent and 50 percent of enrollment. BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Ranked Among Top 5 Biotech Employers Globally BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting